Description

Protein carbonylation occurs when chronically elevated blood sugar levels create a microenvironment for sugars to covalently react with amino acids forming non-enzymatic adducts. Oxidative stress, the excessive production of ROS, can also give rise to the production of protein carbonyls. Over time, these two processess create Advanced Glycation End-products (AGEs) with proteins. The major functional outcome of protein-reactive AGEs is reduced enzymatic activity. Soluble AGEs can also bind and activate the receptor of advanced glycation end-products (RAGE). Receptor-dependent outcomes lead to tissue dysfunction, oxidative stress, and activation of monocytes, endothelial cells and mesangial cells. In Alzheimer’s Disease (AD) protein carbonyls are a marker of oxidative stress in the brain and are elevated in serum and plasma proportional to the cognitive severity. BioVision’s Protein Carbonyl Content Assay Kit uses Fluoroscein-5-Thiosemicarbazide (FTC), a fluorescent probe which covalently reacts with oxidized residues (i.e Cysteine, Lysine, Arginine, Histidine and Aspartic Acid) on proteins. The protein carbonyl content is determined by the generation of a stable fluorometric signal (Ex/Em 485/535 nm) and compared to the protein concentration determined in the BCA Assay to quantitate nmoles of carbonyl/mg protein. The kit is simple, requires no harsh chemicals, can quantitate carbonyls in serum or plasma and produces more reliable and reproducible results than the comparable colorimetric assays. It can detect carbonyl groups in samples with protein concentrations as low as 1 mg/ml

Datasheet

FAQ

-

Downloads